While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
Amazon plans to launch its first prototype satellites for Project Kuiper, an internet-from-space venture, in 2022. It's the first major step in the e-commerce giant's plan to rival SpaceX by building a network of satellites in space, providing internet to rural, underserved communities around the world. Loren Grush, senior science reporter for the Verge, discusses the project and how it could transform internet access moving forward.
The FDA is assessing whether the Moderna vaccine can cause heart problems in adolescents. Professor Peter Pitts, founder of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, discusses what the FDA is looking into and what it means for the millions of kids yet to be vaccinated.
Pfizer posted an earnings beat in its third quarter, with revenue soaring over 134% thanks to solid Covid-19 vaccine sales. Pfizer also raised its outlook for the full-year, expecting revenue to surpass $80 billion. Peter Andersen, CEO & founder of Andersen Capital Management, joined Cheddar Movers to discuss.
Cheddar gets a look at Curiosity Stream's 'Ancient Oceans'; Deep-sea biologist Heather Bracken-Grissom sheds light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths; Tim Janssen, CEO of Sofar Ocean, discusses Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Tim Janssen, CEO of Sofar Ocean, joins 'Cheddar Reveals' to discuss Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Deep-sea biologist Heather Bracken-Grissom joins 'Cheddar Reveals' to shed light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths.
Leaders around the world have come together to discuss plans to bring action towards the Paris Agreement along with solutions on how to solve the evolving climate change crisis at the COP26 Summit. President and CEO of Center for International Environmental Law Carroll Muffett, joined Cheddar to discuss more.
Rachel Cleetus, the policy director and lead economist of the climate and energy program for the Union of Concerned Scientists, joined Cheddar to break down some of the key goals from the COP26 summit and why leaders must focus on the science of climate change instead of getting bogged down by petty politics and the fossil fuel industry. "The main thing they have to do, make sure we're cutting our emissions sharply within this decade because the science shows that we have to cut global emissions in half by 2030 if we're going to meet our goals of averting some of the most catastrophic impacts of climate change," she said.
Coastal cities around the world are grappling with sea level rise. And building a seawall? Not so fast. While a sea wall can be effective in certain scenarios, it can make the effects of sea level rise worse. That’s why municipalities are looking into creative alternatives.
